Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vidrio, Maricela
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone	Active, not recruiting	3	520	Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Type 2 Diabetes	04/25	04/25
Wang, Yihua
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone	Active, not recruiting	3	520	Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Type 2 Diabetes	04/25	04/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	Active, not recruiting	3	1576	Japan, US, RoW	Orforglipron, LY3502970, Semaglutide	Eli Lilly and Company	Type 2 Diabetes	09/25	09/25
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus	Not yet recruiting	2	318	RoW	HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Type 2 Diabetes	04/25	04/25
Narang, Udit
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone	Active, not recruiting	3	520	Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Type 2 Diabetes	04/25	04/25